

Wouter Van Elmpt

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10942260/publications.pdf>

Version: 2024-02-01

127
papers

9,405
citations

71004

43
h-index

48101

92
g-index

128
all docs

128
docs citations

128
times ranked

10668
citing authors

#	ARTICLE	IF	CITATIONS
1	External Validation of a Bayesian Network for Error Detection in Radiotherapy Plans. IEEE Transactions on Radiation and Plasma Medical Sciences, 2022, 6, 200-206.	2.7	4
2	Joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[18F]FDG PET/CT external beam radiation treatment planning in lung cancer V1.0. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1386-1406.	3.3	24
3	Perspective paper about the joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[18F]FDG-PET/CT external beam radiation treatment planning in lung cancer. Radiotherapy and Oncology, 2022, 168, 37-39.	0.3	4
4	Positron emission tomography guided dose painting by numbers of lung cancer: Alanine dosimetry in an anthropomorphic phantom. Physics and Imaging in Radiation Oncology, 2022, 21, 101-107.	1.2	1
5	Prediction Models for Radiation-Induced Neurocognitive Decline in Adult Patients With Primary or Secondary Brain Tumors: A Systematic Review. Frontiers in Psychology, 2022, 13, 853472.	1.1	5
6	Automatic dose verification system for breast radiotherapy: Method validation, contour propagation and DVH parameters evaluation. Physica Medica, 2022, 97, 44-49.	0.4	1
7	Real-world analysis of manual editing of deep learning contouring in the thorax region. Physics and Imaging in Radiation Oncology, 2022, 22, 104-110.	1.2	11
8	Visually guided inspiration breath-hold facilitated with nasal high flow therapy in locally advanced lung cancer. Acta Oncologica, 2021, 60, 567-574.	0.8	10
9	Lymph node response to chemoradiotherapy in oesophageal cancer patients: relationship with radiotherapy fields. Esophagus, 2021, 18, 100-110.	1.0	1
10	Studying local tumour heterogeneity on MRI and FDG-PET/CT to predict response to neoadjuvant chemoradiotherapy in rectal cancer. European Radiology, 2021, 31, 7031-7038.	2.3	12
11	In reply to the letter to the editor: a reply to Fiorino et al: The central role of the radiation oncologist in the multidisciplinary and multiprofessional model of modern radiation therapy. Radiotherapy and Oncology, 2021, 155, e22-e23.	0.3	0
12	Medical Physics and Imaging – A Timely Perspective. Frontiers in Physics, 2021, 9, .	1.0	5
13	Treatment planning and 4D robust evaluation strategy for proton therapy of lung tumors with large motion amplitude. Medical Physics, 2021, 48, 4425-4437.	1.6	11
14	Professional practice changes in radiotherapy physics during the COVID-19 pandemic. Physics and Imaging in Radiation Oncology, 2021, 19, 25-32.	1.2	5
15	The impact of organ-at-risk contour variations on automatically generated treatment plans for NSCLC. Radiotherapy and Oncology, 2021, 163, 136-142.	0.3	14
16	Regional lung avoidance by CT numbers to reduce radiation-induced lung damage risk in non-small cell lung cancer: a simulation study. Acta Oncologica, 2020, 59, 201-207.	0.8	5
17	Multifactorial risk factors for mortality after chemotherapy and radiotherapy for non-small cell lung cancer. Radiotherapy and Oncology, 2020, 152, 117-125.	0.3	19
18	Nitroglycerin as a radiosensitizer in non-small cell lung cancer: Results of a prospective imaging-based phase II trial. Clinical and Translational Radiation Oncology, 2020, 21, 49-55.	0.9	11

#	ARTICLE	IF	CITATIONS
19	Evaluation of measures for assessing time-saving of automatic organ-at-risk segmentation in radiotherapy. <i>Physics and Imaging in Radiation Oncology</i> , 2020, 13, 1-6.	1.2	95
20	Grand challenges for medical physics in radiation oncology. <i>Radiotherapy and Oncology</i> , 2020, 153, 7-14.	0.3	33
21	Professional quality of life and burnout among medical physicists working in radiation oncology: The role of alexithymia and empathy. <i>Physics and Imaging in Radiation Oncology</i> , 2020, 15, 38-43.	1.2	22
22	Overview of artificial intelligence-based applications in radiotherapy: Recommendations for implementation and quality assurance. <i>Radiotherapy and Oncology</i> , 2020, 153, 55-66.	0.3	147
23	External validation of deep learning-based contouring of head and neck organs at risk. <i>Physics and Imaging in Radiation Oncology</i> , 2020, 15, 8-15.	1.2	40
24	Treatment plan quality assessment for radiotherapy of rectal cancer patients using prediction of organ-at-risk dose metrics. <i>Physics and Imaging in Radiation Oncology</i> , 2020, 16, 74-80.	1.2	4
25	The role of alexithymia and empathy on radiation therapists' professional quality of life. <i>Technical Innovations and Patient Support in Radiation Oncology</i> , 2020, 15, 29-36.	0.6	11
26	Professional quality of life and burnout amongst radiation oncologists: The impact of alexithymia and empathy. <i>Radiotherapy and Oncology</i> , 2020, 147, 162-168.	0.3	22
27	CT images with expert manual contours of thoracic cancer for benchmarking auto-segmentation accuracy. <i>Medical Physics</i> , 2020, 47, 3250-3255.	1.6	15
28	Value of combined multiparametric MRI and FDG-PET/CT to identify well-responding rectal cancer patients before the start of neoadjuvant chemoradiation. <i>European Radiology</i> , 2020, 30, 2945-2954.	2.3	12
29	Machine learning applications in radiation oncology: Current use and needs to support clinical implementation. <i>Physics and Imaging in Radiation Oncology</i> , 2020, 16, 144-148.	1.2	39
30	Prevalence of software alerts in radiotherapy. <i>Technical Innovations and Patient Support in Radiation Oncology</i> , 2020, 14, 32-35.	0.6	3
31	Can Atlas-Based Auto-Segmentation Ever Be Perfect? Insights From Extreme Value Theory. <i>IEEE Transactions on Medical Imaging</i> , 2019, 38, 99-106.	5.4	21
32	Inter-observer variability in target delineation increases during adaptive treatment of head-and-neck and lung cancer. <i>Acta Oncologica</i> , 2019, 58, 1378-1385.	0.8	24
33	Challenges and caveats of a multi-center retrospective radiomics study: an example of early treatment response assessment for NSCLC patients using FDG-PET/CT radiomics. <i>PLoS ONE</i> , 2019, 14, e0217536.	1.1	38
34	An Evaluation of Atlas Selection Methods for Atlas-Based Automatic Segmentation in Radiotherapy Treatment Planning. <i>IEEE Transactions on Medical Imaging</i> , 2019, 38, 2654-2664.	5.4	23
35	Longitudinal radiomics of cone-beam CT images from non-small cell lung cancer patients: Evaluation of the added prognostic value for overall survival and locoregional recurrence. <i>Radiotherapy and Oncology</i> , 2019, 136, 78-85.	0.3	48
36	Impact of SBRT fractionation in hypoxia dose painting Accounting for heterogeneous and dynamic tumor oxygenation. <i>Medical Physics</i> , 2019, 46, 2512-2521.	1.6	17

#	ARTICLE	IF	CITATIONS
37	The acute and late toxicity results of a randomized phase II dose-escalation trial in non-small cell lung cancer (PET-boost trial). <i>Radiotherapy and Oncology</i> , 2019, 131, 166-173.	0.3	59
38	Genomics of non-small cell lung cancer (NSCLC): Association between CT-based imaging features and EGFR and K-RAS mutations in 122 patientsâ€”An external validation. <i>European Journal of Radiology</i> , 2019, 110, 148-155.	1.2	22
39	Learning radiation oncology in Europe: Results of the ESTRO multidisciplinary survey. <i>Clinical and Translational Radiation Oncology</i> , 2018, 9, 61-67.	0.9	26
40	Imaging for Target Volume Definition and Response Assessment in Lung Cancer. <i>Progress in Tumor Research</i> , 2018, , 41-47.	0.1	0
41	A secondary analysis of FDG spatio-temporal consistency in the randomized phase II PET-boost trial in stage IIâ€”III NSCLC. <i>Radiotherapy and Oncology</i> , 2018, 127, 259-266.	0.3	4
42	Non-linear conversion of HX4 uptake for automatic segmentation of hypoxic volumes and dose prescription. <i>Acta OncolÃ³gica</i> , 2018, 57, 485-490.	0.8	8
43	Clinical evaluation of atlas and deep learning based automatic contouring for lung cancer. <i>Radiotherapy and Oncology</i> , 2018, 126, 312-317.	0.3	256
44	Comparative evaluation of autocontouring in clinical practice: A practical method using the Turing test. <i>Medical Physics</i> , 2018, 45, 5105-5115.	1.6	58
45	Quantitative computed tomography in radiation therapy: A mature technology with a bright future. <i>Physics and Imaging in Radiation Oncology</i> , 2018, 6, 12-13.	1.2	5
46	Pre-treatment CT radiomics to predict 3-year overall survival following chemoradiotherapy of esophageal cancer. <i>Acta OncolÃ³gica</i> , 2018, 57, 1475-1481.	0.8	58
47	Applicability of a prognostic CT-based radiomic signature model trained on stage I-III non-small cell lung cancer in stage IV non-small cell lung cancer. <i>Lung Cancer</i> , 2018, 124, 6-11.	0.9	39
48	Reply to: â€œComment on: Dualâ€”energy CT quantitative imaging: A comparison study between twinâ€”beam and dualâ€”source CT scanners [Med. Phys. 44(1), 171â€”179 (2017)]â€œ. <i>Medical Physics</i> , 2018, 45, 3997-3998.	1.6	1
49	Autosegmentation for thoracic radiation treatment planning: A grand challenge at AAPM 2017. <i>Medical Physics</i> , 2018, 45, 4568-4581.	1.6	169
50	What you see is (not) what you get: tools for a non-radiologist to evaluate image quality in lung cancer. <i>Lung Cancer</i> , 2018, 123, 112-115.	0.9	2
51	¹⁸ F-fluorodeoxyglucose positron-emission tomography (FDG-PET)-Radiomics of metastatic lymph nodes and primary tumor in non-small cell lung cancer (NSCLC) â€” A prospective externally validated study. <i>PLoS ONE</i> , 2018, 13, e0192859.	1.1	57
52	Decision support systems for personalized and participative radiation oncology. <i>Advanced Drug Delivery Reviews</i> , 2017, 109, 131-153.	6.6	113
53	Regional variability in radiation-induced lung damage can be predicted by baseline CT numbers. <i>Radiotherapy and Oncology</i> , 2017, 122, 300-306.	0.3	21
54	Dualâ€”energy CT quantitative imaging: a comparison study between twinâ€”beam and dualâ€”source CT scanners. <i>Medical Physics</i> , 2017, 44, 171-179.	1.6	101

#	ARTICLE	IF	CITATIONS
55	Defining the hypoxic target volume based on positron emission tomography for image guided radiotherapy – the influence of the choice of the reference region and conversion function. <i>Acta Oncologica</i> , 2017, 56, 819-825.	0.8	13
56	Survival prediction of non-small cell lung cancer patients using radiomics analyses of cone-beam CT images. <i>Radiotherapy and Oncology</i> , 2017, 123, 363-369.	0.3	136
57	A novel concept for tumour targeting with radiation: Inverse dose-painting or targeting the –Low Drug Uptake Volume–. <i>Radiotherapy and Oncology</i> , 2017, 124, 513-520.	0.3	22
58	Automatic selection of lung cancer patients for adaptive radiotherapy using cone-beam CT imaging. <i>Physics and Imaging in Radiation Oncology</i> , 2017, 1, 21-27.	1.2	10
59	PET imaging of zirconium-89 labelled cetuximab: A phase I trial in patients with head and neck and lung cancer. <i>Radiotherapy and Oncology</i> , 2017, 122, 267-273.	0.3	48
60	Quantitative radiomics studies for tissue characterization: a review of technology and methodological procedures. <i>British Journal of Radiology</i> , 2017, 90, 20160665.	1.0	270
61	Radiomics: the bridge between medical imaging and personalized medicine. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 749-762.	12.5	3,216
62	Development of a virtual spacer to support the decision for the placement of an implantable rectum spacer for prostate cancer radiotherapy: Comparison of dose, toxicity and cost-effectiveness. <i>Radiotherapy and Oncology</i> , 2017, 125, 107-112.	0.3	23
63	Feature selection methodology for longitudinal cone-beam CT radiomics. <i>Acta Oncologica</i> , 2017, 56, 1537-1543.	0.8	55
64	Predicting tumor hypoxia in non-small cell lung cancer by combining CT, FDG PET and dynamic contrast-enhanced CT. <i>Acta Oncologica</i> , 2017, 56, 1591-1596.	0.8	15
65	Standard of care in high-dose radiotherapy for localized non-small cell lung cancer. <i>Acta Oncologica</i> , 2017, 56, 1610-1613.	0.8	2
66	Three-dimensional dose evaluation in breast cancer patients to define decision criteria for adaptive radiotherapy. <i>Acta Oncologica</i> , 2017, 56, 1487-1494.	0.8	10
67	Quality assessment of positron emission tomography scans: recommendations for future multicentre trials. <i>Acta Oncologica</i> , 2017, 56, 1459-1464.	0.8	11
68	Influence of gray level discretization on radiomic feature stability for different CT scanners, tube currents and slice thicknesses: a comprehensive phantom study. <i>Acta Oncologica</i> , 2017, 56, 1544-1553.	0.8	183
69	Clinical evaluation of a novel CT image reconstruction algorithm for direct dose calculations. <i>Physics and Imaging in Radiation Oncology</i> , 2017, 2, 11-16.	1.2	18
70	4DCT imaging to assess radiomics feature stability: An investigation for thoracic cancers. <i>Radiotherapy and Oncology</i> , 2017, 125, 147-153.	0.3	61
71	Clustering of multi-parametric functional imaging to identify high-risk subvolumes in non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2017, 125, 379-384.	0.3	23
72	Detection of anatomical changes in lung cancer patients with 2D time-integrated, 2D time-resolved and 3D time-integrated portal dosimetry: a simulation study. <i>Physics in Medicine and Biology</i> , 2017, 62, 6044-6061.	1.6	9

#	ARTICLE	IF	CITATIONS
73	[18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 8-16.	3.3	20
74	Quantitative assessment of Zirconium-89 labeled cetuximab using PET/CT imaging in patients with advanced head and neck cancer: a theragnostic approach. <i>Oncotarget</i> , 2017, 8, 3870-3880.	0.8	48
75	Testâ€Retest Data for Radiomics Feature Stability Analysis: Generalizable or Study-Specific?. <i>Tomography</i> , 2016, 2, 361-365.	0.8	135
76	Validation of dose painting of lung tumours using alanine/EPR dosimetry. <i>Physics in Medicine and Biology</i> , 2016, 61, 2243-2254.	1.6	6
77	The promise of multiparametric imaging in oncology: how do we move forward?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1195-1198.	3.3	7
78	Evaluation of tumour hypoxia during radiotherapy using [18F]HX4 PET imaging and blood biomarkers in patients with head and neck cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 2139-2146.	3.3	51
79	Dual energy CT in radiotherapy: Current applications and future outlook. <i>Radiotherapy and Oncology</i> , 2016, 119, 137-144.	0.3	131
80	Improved dose calculation accuracy for low energy brachytherapy by optimizing dual energy CT imaging protocols for noise reduction using sinogram affirmed iterative reconstruction. <i>Zeitschrift Fur Medizinische Physik</i> , 2016, 26, 75-87.	0.6	28
81	Multiparametric imaging of patient and tumour heterogeneity in non-small-cell lung cancer: quantification of tumour hypoxia, metabolism and perfusion. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 240-248.	3.3	64
82	Quantification of CT-assessed radiation-induced lung damage in lung cancer patients treated with or without chemotherapy and cetuximab. <i>Acta OncolÃ³gica</i> , 2016, 55, 156-162.	0.8	11
83	PET-based dose painting in non-small cell lung cancer: Comparing uniform dose escalation with boosting hypoxic and metabolically active sub-volumes. <i>Radiotherapy and Oncology</i> , 2015, 116, 281-286.	0.3	64
84	A Comparative Study of the Hypoxia PET Tracers [18F]HX4, [18F]FAZA, and [18F]FMISO in a Preclinical Tumor Model. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 351-359.	0.4	139
85	Expanding the scientific role of medical physics in radiotherapy: Time to act. <i>Radiotherapy and Oncology</i> , 2015, 117, 401-402.	0.3	15
86	The influence of gastric filling instructions on dose delivery in patients with oesophageal cancer: A prospective study. <i>Radiotherapy and Oncology</i> , 2015, 117, 442-447.	0.3	10
87	Accurate prediction of target dose-escalation and organ-at-risk dose levels for non-small cell lung cancer patients. <i>Radiotherapy and Oncology</i> , 2015, 117, 453-458.	0.3	21
88	Evaluating Tumor Response of Non-Small Cell Lung Cancer Patients With 18F-Fludeoxyglucose Positron Emission Tomography: Potential for Treatment Individualization. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 376-384.	0.4	27
89	Imaging of tumour hypoxia and metabolism in patients with head and neck squamous cell carcinoma. <i>Acta OncolÃ³gica</i> , 2015, 54, 1378-1384.	0.8	17
90	TH-302 in Combination with Radiotherapy Enhances the Therapeutic Outcome and Is Associated with Pretreatment [18F]HX4 Hypoxia PET Imaging. <i>Clinical Cancer Research</i> , 2015, 21, 2984-2992.	3.2	95

#	ARTICLE	IF	CITATIONS
91	Modern clinical research: How rapid learning health care and cohort multiple randomised clinical trials complement traditional evidence based medicine. <i>Acta Oncol</i> ³ <i>gica</i> , 2015, 54, 1289-1300.	0.8	59
92	Comparison of [18F]-FMISO, [18F]-FAZA and [18F]-HX4 for PET imaging of hypoxia â€“ a simulation study. <i>Acta Oncol</i> ³ <i>gica</i> , 2015, 54, 1370-1377.	0.8	61
93	Repeatability of hypoxia PET imaging using [18F]HX4 in lung and head and neck cancer patients: a prospective multicenter trial. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1840-1849.	3.3	55
94	CT characteristics allow identification of patient-specific susceptibility for radiation-induced lung damage. <i>Radiotherapy and Oncology</i> , 2015, 117, 29-35.	0.3	48
95	Impact of PET reconstruction algorithm and threshold on dose painting of non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2014, 113, 210-214.	0.3	15
96	A qualitative synthesis of the evidence behind elective lymph node irradiation in oesophageal cancer. <i>Radiotherapy and Oncology</i> , 2014, 113, 166-174.	0.3	22
97	<i>In Vivo</i> Quantification of Hypoxic and Metabolic Status of NSCLC Tumors Using [18F]HX4 and [18F]FDG-PET/CT Imaging. <i>Clinical Cancer Research</i> , 2014, 20, 6389-6397.	3.2	81
98	A Longitudinal Evaluation of Partial Lung Irradiation in Mice by Using a Dedicated Image-Guided Small Animal Irradiator. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 696-704.	0.4	44
99	Validation of nonrigid registration in pretreatment and follow-up PET/CT scans for quantification of tumor residue in lung cancer patients. <i>Journal of Applied Clinical Medical Physics</i> , 2014, 15, 240-250.	0.8	5
100	Imaging techniques for tumour delineation and heterogeneity quantification of lung cancer: overview of current possibilities. <i>Journal of Thoracic Disease</i> , 2014, 6, 319-27.	0.6	17
101	Characterization of tumor heterogeneity using dynamic contrast enhanced CT and FDG-PET in non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2013, 109, 65-70.	0.3	37
102	â€“Rapid Learning health care in oncologyâ€™ â€“ An approach towards decision support systems enabling customised radiotherapyâ€™. <i>Radiotherapy and Oncology</i> , 2013, 109, 159-164.	0.3	175
103	Predicting outcomes in radiation oncologyâ€” multifactorial decision support systems. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 27-40.	12.5	329
104	Hypoxia imaging with [18F]HX4 PET in NSCLC patients: Defining optimal imaging parameters. <i>Radiotherapy and Oncology</i> , 2013, 109, 58-64.	0.3	81
105	State of the Art Radiation Therapy for Lung Cancer 2012: A Glimpse of the Future. <i>Clinical Lung Cancer</i> , 2013, 14, 89-95.	1.1	38
106	Effects of quantum noise in 4D-CT on deformable image registration and derived ventilation data. <i>Physics in Medicine and Biology</i> , 2013, 58, 7661-7672.	1.6	15
107	Quantification of radiation-induced lung damage with CT scans: The possible benefit for radiogenomics. <i>Acta Oncol</i> ³ <i>gica</i> , 2013, 52, 1405-1410.	0.8	45
108	Prognostic value of metabolic metrics extracted from baseline positron emission tomography images in non-small cell lung cancer. <i>Acta Oncol</i> ³ <i>gica</i> , 2013, 52, 1398-1404.	0.8	44

#	ARTICLE	IF	CITATIONS
109	Validation of three deformable image registration algorithms for the thorax. Journal of Applied Clinical Medical Physics, 2013, 14, 19-30.	0.8	25
110	Dependence of ventilation image derived from 4D CT on deformable image registration and ventilation algorithms. Journal of Applied Clinical Medical Physics, 2013, 14, 150-162.	0.8	13
111	Should Patient Setup in Lung Cancer Be Based on the Primary Tumor? An Analysis of Tumor Coverage and Normal Tissue Dose Using Repeated Positron Emission Tomography/Computed Tomography Imaging. International Journal of Radiation Oncology Biology Physics, 2012, 82, 379-385.	0.4	8
112	Is high-dose stereotactic body radiotherapy (SBRT) for stage I non-small cell lung cancer (NSCLC) overkill? A systematic review. Radiotherapy and Oncology, 2012, 105, 145-149.	0.3	89
113	The PET-boost randomised phase II dose-escalation trial in non-small cell lung cancer. Radiotherapy and Oncology, 2012, 104, 67-71.	0.3	205
114	Response Assessment Using ¹⁸ F-FDG PET Early in the Course of Radiotherapy Correlates with Survival in Advanced-Stage Non-Small Cell Lung Cancer. Journal of Nuclear Medicine, 2012, 53, 1514-1520.	2.8	106
115	Identification of residual metabolic-active areas within NSCLC tumours using a pre-radiotherapy FDG-PET-CT scan: A prospective validation. Lung Cancer, 2012, 75, 73-76.	0.9	97
116	Assessment of tumour size in PET/CT lung cancer studies: PET- and CT-based methods compared to pathology. EJNMMI Research, 2012, 2, 56.	1.1	57
117	Early CT and FDG-metabolic tumour volume changes show a significant correlation with survival in stage III small cell lung cancer: A hypothesis generating study. Radiotherapy and Oncology, 2011, 99, 172-175.	0.3	42
118	Radiotherapy with curative intent for lung cancer: A continuing success story. Radiotherapy and Oncology, 2011, 101, 237-239.	0.3	7
119	Optimal gating compared to 3D and 4D PET reconstruction for characterization of lung tumours. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 843-855.	3.3	109
120	Volume or Position Changes of Primary Lung Tumor During (Chemo-)Radiotherapy Cannot Be Used as a Surrogate for Mediastinal Lymph Node Changes: The Case for Optimal Mediastinal Lymph Node Imaging During Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2011, 79, 89-95.	0.4	19
121	3D dose delivery verification using repeated cone-beam imaging and EPID dosimetry for stereotactic body radiotherapy of non-small cell lung cancer. Radiotherapy and Oncology, 2010, 94, 188-194.	0.3	35
122	EPID dosimetry must soon become an essential component of IMRT quality assurance. Medical Physics, 2009, 36, 4325-4327.	1.6	11
123	Evaluation of nonrigid registration models for interfraction dose accumulation in radiotherapy. Medical Physics, 2009, 36, 4268-4276.	1.6	73
124	3D In Vivo Dosimetry Using Megavoltage Cone-Beam CT and EPID Dosimetry. International Journal of Radiation Oncology Biology Physics, 2009, 73, 1580-1587.	0.4	71
125	The next step in patient-specific QA: 3D dose verification of conformal and intensity-modulated RT based on EPID dosimetry and Monte Carlo dose calculations. Radiotherapy and Oncology, 2008, 86, 86-92.	0.3	83
126	Transition from a simple to a more advanced dose calculation algorithm for radiotherapy of non-small cell lung cancer (NSCLC): Implications for clinical implementation in an individualized dose-escalation protocol. Radiotherapy and Oncology, 2008, 88, 326-334.	0.3	30

#	ARTICLE	IF	CITATIONS
127	A literature review of electronic portal imaging for radiotherapy dosimetry. Radiotherapy and Oncology, 2008, 88, 289-309.	0.3	384